Silver Andrew Jacob, the Chief Financial Officer of CRISPR Therapeutics AG, has reported significant stock option and restricted stock unit acquisitions in a recent SEC filing. This event is noteworthy as it underscores the alignment of executive compensation with company performance in the biotech industry.

Background

CRISPR Therapeutics AG, identified by CIK 0001674416, operates in the biological products sector. The company focuses on developing transformative gene-based medicines for serious diseases. Jacob's recent filings include a Form 4 submitted on October 28, 2026, and additional filings earlier that month.

What the Filing Says

According to the filing (accession number 0001193125-26-436444), Jacob acquired 18,000 stock options with an exercise price of $49.01 and 9,000 restricted stock units on October 26, 2026. The filing states, "This option was granted...with respect to 18,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026." The restricted stock units will vest over four years, with the first quarter vesting on October 26, 2027.

Impact

This acquisition may affect CRISPR Therapeutics' shareholders and employees by reinforcing the company's commitment to aligning executive rewards with long-term performance. The biotech industry, particularly companies focused on biological products, may see similar trends as they strive to attract and retain top talent.

What's Next

The filing does not say what happens next.